Sai Life Sciences Ltd upgraded to IND AA/Stable on ₹7,690 million bank loan facilities
- India Ratings upgraded the long-term rating from IND AA-/Positive; short-term rating affirmed at IND A1+.
- FY26 consolidated revenue was ₹21,925 million with a 28.8% EBITDA margin; 1HFY27 revenue was ₹12,129 million with a 27.6% margin.
- Planned FY27 capex of ₹11–13 billion may moderate leverage and constrain free cash flow; capacity ramp-up and asset utilisation are key monitorables.